Renovaro (NASDAQ:RENB) Shares Down 1.3% - Time to Sell?

Renovaro Inc. (NASDAQ:RENB - Get Free Report) traded down 1.3% during trading on Monday . The company traded as low as $0.28 and last traded at $0.29. 1,789,053 shares traded hands during mid-day trading, an increase of 15% from the average session volume of 1,559,300 shares. The stock had previously closed at $0.29.

Renovaro Stock Up 2.7%

The company's 50 day moving average is $0.33 and its 200 day moving average is $0.62.

Institutional Trading of Renovaro

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in Renovaro by 48.4% in the fourth quarter. Geode Capital Management LLC now owns 2,332,634 shares of the company's stock worth $1,949,000 after purchasing an additional 760,344 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Renovaro by 49.5% in the 4th quarter. Northern Trust Corp now owns 889,357 shares of the company's stock worth $743,000 after buying an additional 294,468 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Renovaro by 82.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 362,126 shares of the company's stock worth $303,000 after buying an additional 163,160 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Renovaro by 280.4% during the fourth quarter. JPMorgan Chase & Co. now owns 353,833 shares of the company's stock valued at $296,000 after buying an additional 260,823 shares during the period. Finally, Cantor Fitzgerald L. P. raised its holdings in shares of Renovaro by 200.0% in the fourth quarter. Cantor Fitzgerald L. P. now owns 300,000 shares of the company's stock valued at $251,000 after acquiring an additional 200,000 shares in the last quarter. Institutional investors own 71.41% of the company's stock.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.